Logo

As Expected, Transgenomic Closes $15M Private Placement of Common Stock

Oct 31, 2005

NEW YORK, Oct. 31 (GenomeWeb News) - Transgenomic has completed its private placement of common stock to a group of institutional investors led by Lehman Brothers, the company said today.

 

As GenomeWeb News  previously reported, the transaction was originally priced at $1.01 per share for 15 million shares. Acompany spokesperson confirmed the final amount today as "rounded off to approximately $15 million."

 

Net proceeds from the sale were used to repay the company's debt of approximately $8.6 million with Laurus Master Fund. The remainder was retained for working capital.

 

The Omaha-Neb.-based company has committed to preparing and filing a registration statement covering the resale within 30 days of closing.

Breaking News
The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.